Overcoming data mining and visualization challenges is critical to the success of data science. Converting data to a visual framework such as data clustering allows trend recognition which in turn can help with decision making. This approach to insight generation linked with human experience will be very powerful for all aspects of data sciences.
Dr. Shaywitz focuses on transformational opportunities and implementation challenges presented by emerging technologies in the context of biopharmaceuticals, from NGS and cell therapies to digital biomarkers and the meaningful application of AI. A graduate of Harvard College and the MD/PhD program at Harvard/MIT, Dr. Shaywitz trained in medicine and endocrinology at MGH, and conducted post-doctoral research in the Melton Lab at Harvard. He subsequently worked at Merck, Boston Consulting Group, Theravance, and DNAnexus, a Silicon Valley cloud genomics company where he served as Chief Medical Officer. From 2017-2019, he was Senior Partner in the Palo Alto office of Takeda Ventures, Inc., serving on multiple boards. He recently founded "Astounding HealthTech," providing advisory services to biopharma leaders and digital/data startup founders. Dr. Shaywitz writes extensively about innovation and biopharma, and since 2015 has co-hosted the popular “Tech Tonics” podcast with Lisa Suennen. He is an adjunct scholar at the AEI.
Dr. Patel is a physician engineer, informatician, active teacher and researcher. He has a special interest in machine and deep learning, mathematical modeling of biological processes, informatics and 3D printing. He is Chair of Department of Radiology, Medical Director for 3D Imaging and Printing Laboratory for Geisinger and leads the informatics efforts in Radiology at Geisinger. Dr. Patel has published 90 research articles, review articles, textbook chapters and abstracts and has given several invited lectures at regional, national and international conferences. Dr. Patel is an electrical engineer and clinically an Interventional Radiologist. His clinical research interests include dialysis access management and interventional oncology. He led Radiology and Interventional Radiology simulation program at Penn Medicine Clinical Simulation Center. For eight years, he has been in various leadership positions at Geisinger. He is boarded in Diagnostic Radiology, Interventional Radiology and Clinical Informatics and is a Fellow of the Society of Interventional Radiology.
Machines And Humans – Perfect Together
Much has been said about the coming of AI and obsolesce of humans in healthcare. This hype and fear are nonproductive. The real question for healthcare professionals should be: how do we use AI to better care of patients while containing costs and improving patient satisfaction? Initial efforts have largely focused on helping physicians and broader efforts are beginning to use AI for finance, operations and value.
Kaisa Helminen leads Aiforia Technologies, a medical software company in a rapid expansion phase. Their Aiforia® Cloud is transforming clinical pathology and medical research by bringing deep learning AI to assist and augment human experts in image analysis. As a result, patients will have faster, more accurate diagnosis and more personalized care. Kaisa has a strong background in the life science industry, where she has gained close to 20 years of experience in the global business. Previously she has worked for both midsize and large international life science companies, including Thermo Fisher Scientific, Sartorius and Finnzymes, in sales, marketing and business development positions. Kaisa holds a M.Sc. degree in biochemistry from the University of Helsinki.
Dr. Martin Stumpe serves as the Senior Vice President for Data Science at Tempus, where he is responsible for the vision and execution of using data science and machine learning to advance the precision medicine agenda of the company. Prior to joining Tempus, he founded and led the Cancer Pathology project at Google, which uses artificial intelligence to increase the accuracy in image-based cancer detection and grading. Earlier in his career, Dr. Stumpe was part of the Kepler team at NASA Ames Research Center in Mountain View, California, where he was responsible for the development of algorithms to detect extrasolar planets from stellar light curves. Before that, he was a postdoctoral researcher at Stanford University in the lab of Vijay Pande, focusing on molecular dynamics simulations to study chaperone-induced protein folding. Dr. Stumpe holds a PhD in Physics from the Max-Planck-Institute for Biophysical Chemistry in Goettingen, Germany.
Dr. Khozin is an oncologist, physician-scientist, and research affiliate at MIT. He leads the global data strategy for Janssen R&D/J&J, focusing on digital health, real-world data, and advanced quantitative methods (including AI/ML). He joined the company from FDA’s Oncology Center of Excellence, where he led the Center’s bioinformatics initiatives. He was also the founder of Information Exchange and Data Transformation (INFORMED), FDA’s first data science and technology incubator for de-risking solutions through internal R&D and strategic partnerships for improving biomedical research and advancing public health priorities. Prior to his tenure in the federal government, Dr. Khozin was the cofounder of Hello Health, where he developed an integrated telemedicine, point-of-care data visualization, and analytical platform for optimizing patient care and clinical research. The company’s core technology offerings were first operationalized in a multidisciplinary network of clinics called SKMD that he founded and for which he served as the chief medical officer.